title: Advanced antigen delivery of murine survivin: chimeric virus-like particles in cancer vaccine research.
abstract: Success in cancer immunotherapy depends on the identification and efficient targeting of specific tumor-associated antigens. Two pivotal strategies to prime patients' immune system against malignant cells are tumor-specific adoptive T-cell therapy and tumor-specific vaccination. Here, we will focus on immunotherapeutic vaccination and discuss the advantages and disadvantages of different strategies to deliver tumor-specific T-cell epitopes. A particular focus will be put on virus-like particles (VLPs) as vehicle to deliver tumor-specific epitopes in the context of full-length proteins, as multi-epitope constructs or as individual tumor-associated T-cell epitopes. VLPs represent non-infectious and non-replicating antigen delivery systems devoid of any nucleic acid. They constitute innovative immunotherapeutic agents against cancer due to their superior, adjuvant-like antigenicity. We will present various tumor-associated antigens currently in different stages of development including survivin, as promising candidates for targeted tumor therapies.
authors.affiliation: Siegfried Biologics GmbH, Heinrich-Hertz-Str. 1b, 14532 Kleinmachnow, Germany;
authors.forename: Thomas
authors.initials: T
authors.lastname: Schumacher
authors.forename: Claus
authors.initials: C
authors.lastname: Ruehland
authors.forename: Christine
authors.initials: C
authors.lastname: Schultheiss
authors.forename: Marc
authors.initials: M
authors.lastname: Brinkman
authors.forename: Franz
authors.initials: F
authors.lastname: Roedel
authors.forename: Christian O A
authors.initials: CO
authors.lastname: Reiser
authors.forename: Juergen
authors.initials: J
authors.lastname: Hess
authors.forename: Christoph
authors.initials: C
authors.lastname: Reichel
keywords: cancer; cell-mediated immunity; survivin; vaccines; virus-like particles